Pricing Log in Create free account
Friday 6 November 2026 Export MRNA’s income statement to Excel — free account

Moderna, Inc.

MRNA Healthcare Biotechnology

Moderna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024.

Revenue
+29.2%
EPS
+178.4%
Free cash flow
−90.9%
Total debt
+1,765.6%

Quarter to September 2026, against a year earlier

253.57 12.11 +5.02%
Market cap
$96.4B
P/E
0.0×
Fwd P/E
−26.1×
Dividend yield
—
F-score
3/9
Altman Z
2.46
Beneish M
−3.52
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Moderna, Inc. 10-Q filed Aug 1, 2025

Fiscal Q2 2025 · Period ended Jun 30, 2025 · Filed · accepted 4:03 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed May 1, 2025: no comparison — the Item was not found